S. aureus

BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

Retrieved on: 
Martedì, Maggio 21, 2024
Patient, Infection, Staphylococcus aureus, ESCMID, Pseudomonas aeruginosa, Therapy, APT, NESS, Orphan, OrbiMed, Cystic Fibrosis Foundation, Cystic fibrosis, DFO, S. aureus, Șaeș, Abstract, Part, Phage therapy, FEV1, Pharmaceutical industry

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided business and program updates for the first quarter ended March 31, 2024. BiomX is announcing merged financial reporting for the first time following the closing of its merger with Adaptive Phage Therapeutics, Inc. (“APT”) in March 2024 and a concurrent $50 million private placement.

Key Points: 
  • and NESS ZIONA, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided business and program updates for the first quarter ended March 31, 2024.
  • General and administrative expenses were $2.7 million for the first quarter of 2024, compared to $1.6 million for the first quarter of 2023.
  • Net loss was $17.3 million for the first quarter of 2024, compared to $6.4 million for the first quarter of 2023.
  • ET to discuss its first quarter 2024 financial results and to provide a corporate update.

Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

Retrieved on: 
Venerdì, Maggio 17, 2024
Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Patient, MRSA, Investigational New Drug, Toxicity, Staphylococcus epidermidis, FDA, IND, Skin, Staphylococcus, Engineering, Society, Growth, S. aureus, Inflammation, LEKTI, Annual general meeting, Pharmaceutical industry

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company’s platform and pipeline.

Key Points: 
  • Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company’s platform and pipeline.
  • “We are pleased to announce the first publication of preclinical data around ATR-04 in EGFR inhibitor (EGFRi)-associated dermal toxicity,” said Travis Whitfill, Azitra’s co-founder and COO.
  • The data in the oral presentations today showcase the preclinical development of ATR-04.
  • Together, the data show that ATR-04 can address multiple drivers of EGFRi-induced skin toxicity.

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Retrieved on: 
Martedì, Aprile 2, 2024
S. aureus, Risk, Patient, Tissue, Staphylococcus aureus, Infection, CDC, Staphylococcus, Animal, Antigen, Vaccine

In the animal studies, the EVX-B1 antigens significantly reduced disease burden.

Key Points: 
  • In the animal studies, the EVX-B1 antigens significantly reduced disease burden.
  • Birgitte Rønø, Chief Scientific Officer at Evaxion, expresses enthusiasm: “We are very thrilled about the encouraging data and believe that our EVX-B1 vaccine antigens hold the potential for efficacy in human trials – a milestone that previous vaccine attempts have failed to achieve.”
    There is no S. aureus vaccine available for human use.
  • Also, the presence of antibiotic-resistant S. aureus is limiting available treatment options.
  • The Centers for Disease Control and Prevention (CDC) has reported 120,000 bloodstream infections associated with S. aureus in the US annually.

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

Retrieved on: 
Lunedì, Febbraio 12, 2024
Pseudomonas aeruginosa, Infection, ICU, Escherichia coli, Catheter, Acinetobacter baumannii, FDA, Food, Carbapenem, Bloodstream infections, Risk, Intensive care medicine, Bacteria, World Health Organization, Patient, Septic shock, S. aureus, Mortality

LEXINGTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded T2Bacteria® Panel, adding the capability to detect another bacterial species, Acinetobacter baumannii (A. baumannii), to the expansive panel.

Key Points: 
  • LEXINGTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded T2Bacteria® Panel, adding the capability to detect another bacterial species, Acinetobacter baumannii (A. baumannii), to the expansive panel.
  • “We are thrilled to receive the FDA 510(k) clearance for the expanded T2Bacteria Panel, to include the detection of A. baumannii, as we believe it will lead to increased adoption of our proprietary direct-from-blood platform,” stated John Sperzel, Chairman and CEO of T2 Biosystems.
  • The FDA-cleared T2Bacteria Panel now detects E. faecium, S. aureus, K. pneumoniae, P. aeruginosa, E. coli, and A. baumannii.
  • Rapid detection of these pathogens is essential to getting infected patients on the appropriate antimicrobial therapy and improving clinical outcomes.

LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus

Retrieved on: 
Martedì, Dicembre 19, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Rabbit, Infection, Multimedia, NIAID, Toxoid, Administration, Staphylococcus aureus, Mouse, Doctor of Philosophy, Recurrence, DHSC, Human services, REPAIR, Education, Bangladesh Technical Education Board, S. aureus, Staphylococcus, Patient, Development, BMBF, Social work, Skin, CARB-X, Vaccine

LimmaTech Biologics and AbVacc announced today a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus).

Key Points: 
  • LimmaTech Biologics and AbVacc announced today a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus).
  • LimmaTech also receives an exclusive option, executable post Phase 1 read-out, to acquire full rights to the program.
  • The vaccine candidate contains weakened forms of toxins, referred to as toxoids, that would normally be secreted by the pathogen to cause an infection.
  • Preclinical studies in mice and rabbits demonstrated strong neutralizing activity against several clinically relevant forms of S. aureus infection.

PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

Retrieved on: 
Martedì, Novembre 14, 2023
Webcast, Research, POC, European Medicines Agency, Lysin, Therapy, Infection, Conference call, Bank statement, S. aureus, Escherichia coli, S, Risk, Mortality, Phage therapy, EMA, ANSM, Patient, CET, AAC, FDA, Klebsiella pneumoniae, Fungal infection, Health, Pseudomonas aeruginosa, Partnership, CMC, IVD, EI, Cryptocurrency, Pharmaceutical industry, Dietary supplement, Medical device, Vaccine, Conference, Bloodstream infections

The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.

Key Points: 
  • The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.
  • Key financial figures for the first nine months of 2023 compared with the same period of the previous year are summarized below.
  • In the context of the Erytech-Pherecydes merger, PHAXIAM’s consolidated financial statements in IFRS standards include ex-Pherecydes financial results as from the date of the merger, i.e.
  • Consequently, PHAXIAM’s P&L information for the first 9 months of 2023 include 9 months of ex-Erytech activities and ex-Pherecydes activities since June 23, 2023.

Thermo Fisher Scientific Introduces New Sample Preparation Solutions to Simplify and Automate Respiratory Diagnostic Testing

Retrieved on: 
Lunedì, Dicembre 11, 2023
Manufacturing, Other Manufacturing, Science, Other Science, Research, Data management, Thermo Fisher Scientific, DNA, RSV, RUO, Laboratory information management system, S. aureus, PCR, Kingfisher, Mindful Scientific Inc., Laboratory, Automation, Mycobacterium tuberculosis, SARS-CoV-2, IVD, RNA, LIS, LIMS, Vaccine, Medical device

Together these products provide laboratories with an in vitro diagnostic (IVD) and in vitro diagnostic regulation (IVD-R) approved automated sample preparation solutions for increased confidence in downstream results.

Key Points: 
  • Together these products provide laboratories with an in vitro diagnostic (IVD) and in vitro diagnostic regulation (IVD-R) approved automated sample preparation solutions for increased confidence in downstream results.
  • Clinical laboratories that perform respiratory testing need to generate the highest quality results.
  • “The KingFisher Apex Dx system builds on decades of product expertise and innovation customers have come to trust in our KingFisher instrument line,” said Ellie Mahjubi, vice president and general manager, sample preparation at Thermo Fisher Scientific.
  • For more information including technical specifications, applications, and consumables, please visit www.thermofisher.com/kingfisherapex and MagMAX Dx Viral/Pathogen Nucleic Acid Isolation Kit.

Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Venerdì, Novembre 3, 2023
FDA, Research, Sale, National Institute of Allergy and Infectious Diseases, AstraZeneca, Ventilator-associated pneumonia, Antibiotic, Cystic Fibrosis Foundation, VAP, Omicron, NIAID, European Medicines Agency, OTCQB, Tenant, Development, Pharmacokinetics, Priority review, Data monitoring committee, Common stock, QIDP, Pseudomonas aeruginosa, Expense, Nature Communications, COVID-19, Cystic fibrosis, S. aureus, Emory University, EMA, Staphylococcus, Gallium, NIH, Safety, Infection, Patient, Administration, Mab, BLA, Bangladesh Technical Education Board, Respiratory tract, DSMB, ICU, Pharmaceutical industry, Vaccine, Security (finance)

LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023.

Key Points: 
  • OTCQB companies must be current in their financial reporting and undergo an annual verification and management certification process.
  • We remain optimistic of successful outcomes from these efforts in the coming months,” commented Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals.
  • Due to fair value option valuation of our notes payable, there was no interest expense recorded during the third quarter of 2023.
  • Other Income: Other income increased to $26,000 for the quarter ended September 30, 2023, compared to approximately $23,000 for the quarter ended September 30, 2022.

PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

Retrieved on: 
Martedì, Ottobre 24, 2023
Fungal infection, Stroke, Phage therapy, Staphylococcus aureus, Incidence, National Agency for Food and Drug Administration and Control, Heart, Medication, Teaching hospital, Hope, Mortality, Endocarditis, Safety, ANSM, Infection, CEST, Pharmacokinetics, Endocardium, Clinical trial, S. aureus, Jean-Pierre du Teil, Bacteria, Blood, S, Therapy, Patient, Heart failure, CPP, Pharmaceutical industry

Endocarditis is an infection of the endocardium (inner lining of the heart) and valves, usually caused by bacteria.

Key Points: 
  • Endocarditis is an infection of the endocardium (inner lining of the heart) and valves, usually caused by bacteria.
  • The main cause of endocarditis infections, S. aureus, is responsible for around 30%1 of cases.
  • Pascal Birman, Chief Medical Officer of PHAXIAM Therapeutics, stated: "This phase 1 study was designed primarily to assess the safety and pharmacokinetics of our anti-S. aureus phages in the treatment of endocarditis infections.
  • The treatment of endocarditis infections caused by S. aureus using phage therapy could thus offer a major alternative and hope to many patients who have reached a therapeutic impasse.”

LEO Pharma Presents Adbry® (tralokinumab-ldrm) Data at 2023 Fall Clinical Dermatology Conference

Retrieved on: 
Venerdì, Ottobre 20, 2023
Biotechnology, Pharmaceutical, Health, Janus, Tralokinumab, Patient, Adolescence, AD, Ageing, Catalog, Leo Pharma, Conference, Systematic review, Research, RWE, Meta-analysis, TRACE, Various, Disease, S. aureus, Safety, Atopic dermatitis, LEO, Pharmaceutical industry, Vaccine

LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of new clinical and real-world data around tralokinumab-ldrm in the treatment of moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of new clinical and real-world data around tralokinumab-ldrm in the treatment of moderate-to-severe atopic dermatitis (AD).
  • The drug is marketed in the U.S. as Adbry® for adult patients (aged 18+ years) with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
  • The findings are being presented across 12 posters at the 2023 Fall Clinical Dermatology Conference taking place in Las Vegas, Nevada, from October 19-22, 2023.1-12
    “We are thrilled to present such a wealth of tralokinumab-ldrm data, which will further develop our understanding of how to meet the needs of patients living with atopic dermatitis,” says Kreesten Meldgaard Madsen, Chief Development Officer, LEO Pharma.
  • “The breadth and depth of LEO Pharma data being presented at the Fall Clinical Dermatology Conference this year will showcase our leadership in the medical dermatology space and our continued commitment to the whole patient community.